Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179494 | 0.87 | RXRA (0.37) | CYP4F2CYP4A11MGLLTBXAS1KDM4E | |
| SCHEMBL25917448 | 0.85 | ALDH1A1 (0.32) | CYP4F2CYP4A11ALDH1A1GAAKDM4E | |
| SCHEMBL30723993 | 0.82 | KDM4E (0.30) | ALDH1A1KDM4E | |
| SCHEMBL25918022 | 0.82 | KDM4E (0.30) | ALDH1A1KDM4E | |
| SCHEMBL25917431 | 0.82 | CYP4F2 (0.43) | CYP4F2CYP4A11MGLLTBXAS1CTNNB1 | |
| SCHEMBL25917446 | 0.80 | RXRA (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL30723887 | 0.76 | RXRA (0.31) | — | |
| SCHEMBL24179526 | 0.76 | RXRA (0.31) | — | |
| SCHEMBL30758953 | 0.73 | RXRA (0.39) | CYP4F2CYP4A11MGLLTBXAS1CTNNB1 | |
| SCHEMBL30724136 | 0.71 | ALOX5AP (0.39) | CYP4F2CYP4A11CTNNB1ALDH1A1HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006776-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND MEDICAL USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | SLC5A11, CYP11B2, CYP4F11 | CYP4F2 33/4885CYP4A11 4/4885MGLL 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.